This site is intended for health professionals only

At the heart of general practice since 1960

MHRA pulls lumiracoxib

The Medicines and Healthcare Products Regulatory Agency (MHRA) has decided to suspend the license for lumiracoxib because of safety concerns over potential liver damage.

The MHRA is urging patients on the osteoarthritis drug to see their doctor as soon as convenient, after a review of available evidence identified serious liver reactions even with the licensed 100mg dose – in some cases after short-term use.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say